Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy

被引:66
作者
Neuschatz, AC
DiPetrillo, T
Safaii, H
Price, LL
Schmidt-Ullrich, RK
Wazer, DE
机构
[1] Tufts New England Med Ctr, Dept Radiat Oncol, Boston, MA USA
[2] Tufts New England Med Ctr, Dept Pathol, Boston, MA USA
[3] Tufts New England Med Ctr, Dept Clin Care Res, Boston, MA USA
[4] Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA
关键词
breast-conserving treatment; tumor margins; radiation boost; dose escalation;
D O I
10.1002/cncr.10981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. A prospectively applied treatment policy for breast-conserving therapy used margin assessment as the exclusive guide to the intensity of radiation therapy directed at the tumor bed. METHODS. From 1982 to 1994, 498 women with 509 Stage I/II breast carcinomas with a median follow-up of 121 months were treated. Final margin status (FMS) categories were defined as greater than 5 rum, greater than 2-5 mm, greater than 0-2 mm, and positive. For margins less than or equal to 2 rum or indeterminate, reexcisions were performed if feasible. All patients received whole breast irradiation to 50.0-50.4 Gy. Final tumor bed boosts as a function of FMS were as follows: no residual on reexcision, no boost performed; FMS greater than 5 mm, boost of 10 Gy; FMS greater than 2-5 mm, boost of 14 Gy; FMS greater than 0-2 mm or positive, boost of 20 Gy. Cases were analyzed for local failure with respect to histology, age, tumor size, excision volume, reexcision, and total dose. RESULTS. FMS was positive, greater than 0-2 mm, greater than 2-5 mm, and greater than 5 mm, and no residual tumor on reexcision in 21%, 20%, 17%, 14%, and 28% of cases, respectively. At 12 years, Kaplan-Meier local failure rates were 17% for FMS positive, 9% for FMS greater than 0-2 mm, 5% for FMS greater than 2-5 mm, 0% for FMS greater than 5 mm, and 6% for specimens without evidence of residuum on reexcision (P = 0.009). Patients 45 years old and younger had a 12-year local failure rate of 15% whereas patients older than 45 years had a 12-year local failure rate of 6% (P = 0.01). On multivariate analysis, young age (P = 0.03) predicted increased local failure rate, whereas margins that were less than or equal to 2 mm or positive predicted late (> 5 years) but not early (less than or equal to5 years) recurrence (P = 0.003). CONCLUSIONS. Graded tumor bed dose escalation in response to FMS results in very low rates of local failure over the first 5 years for all FMS categories. However, tumors with close/positive margins have significantly increased local failure rates after 5 years of follow-up even with increased radiation boost dose. In addition, graded tumor bed dose escalation does not fully overcome the adverse influence of young age.
引用
收藏
页码:30 / 39
页数:10
相关论文
共 44 条
[1]   LOCAL FAILURE AND MARGIN STATUS IN EARLY-STAGE BREAST-CARCINOMA TREATED WITH CONSERVATION SURGERY AND RADIATION-THERAPY [J].
ANSCHER, MS ;
JONES, P ;
PROSNITZ, LR ;
BLACKSTOCK, W ;
HEBERT, M ;
REDDICK, R ;
TUCKER, A ;
DODGE, R ;
LEIGHT, G ;
IGLEHART, JD ;
ROSENMAN, J .
ANNALS OF SURGERY, 1993, 218 (01) :22-28
[2]   Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].
Bartelink, H ;
Horiot, J ;
Poortmans, P ;
Struikmans, H ;
Van den Bogaert, W ;
Barillot, I ;
Fourquet, A ;
Borger, J ;
Jager, J ;
Hoogenraad, W ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387
[3]   Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update [J].
Clark, RM ;
Whelan, T ;
Levine, M ;
Roberts, R ;
Willan, A ;
McCulloch, P ;
Lipa, M ;
Wilkinson, RH ;
Mahoney, LJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1659-1664
[4]   REANALYSIS AND RESULTS AFTER 12 YEARS OF FOLLOW-UP IN A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY WITH LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
ANDERSON, S ;
REDMOND, CK ;
WOLMARK, N ;
WICKERHAM, DL ;
CRONIN, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22) :1456-1461
[5]   Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [J].
Fisher, B ;
Dignam, J ;
Mamounas, EP ;
Costantino, JP ;
Wickerham, DL ;
Redmond, C ;
Wolmark, N ;
Dimitrov, NV ;
Bowman, DM ;
Glass, AG ;
Atkins, JN ;
Abramson, N ;
Sutherland, CM ;
Aron, BS ;
Margolese, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :1982-1992
[6]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[7]  
FISHER B, 1993, P AM SOC CLIN ONCOL, V12, pA79
[8]   Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy [J].
Freedman, G ;
Fowble, B ;
Hanlon, A ;
Nicolaou, N ;
Fein, D ;
Hoffman, J ;
Sigurdson, E ;
Boraas, M ;
Goldstein, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (05) :1005-1015
[9]   LONG-TERM OUTCOME FOLLOWING BREAST-CONSERVING SURGERY AND RADIATION-THERAPY [J].
GAGE, I ;
RECHT, A ;
GELMAN, R ;
NIXON, AJ ;
SILVER, B ;
BORNSTEIN, BA ;
HARRIS, JR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (02) :245-251
[10]   PRIMARY RADIATION-THERAPY FOR EARLY BREAST-CANCER - THE EXPERIENCE AT THE JOINT CENTER FOR RADIATION-THERAPY [J].
HARRIS, JR ;
BOTNICK, L ;
BLOOMER, WD ;
CHAFFEY, JT ;
HELLMAN, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (11) :1549-1552